Short answer
ACADIA PHARMACEUTICALS INC (ACAD) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers financial results for the nine months ended September 30, 2026.
ACADIA PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers financial results for the nine months ended September 30, 2026
- Exhibit 99.1 contains the detailed results and management commentary
- Investor focus: revenue trends, operating expenses, cash position, and updated outlook in the exhibit
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $342.3M, up 23% YoY, with DAYBUE $140.1M, up 39%, and NUPLAZID $202.2M, up 14% GAAP
- 2026 DAYBUE guidance raised to $505M-$520M, signaling stronger commercial uptake and improved visibility for the growth franchise
- Total revenue guidance narrowed to $1.265B-$1.295B, while NUPLAZID guidance narrowed to $760M-$775M
- Net income fell to $53.5M from $71.8M as SG&A rose to $159.2M and income tax expense reached $26.9M
- Remlifanserin advanced toward Phase 3 in Alzheimer’s disease psychosis, with additional RADIANT data due November 17 and 2027 LBDP readout guidance
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ACADIA PHARMACEUTICALS INC 8-K filings
Get the next ACAD 8-K as it lands
Follow ACAD for push alerts, or ask the research agent what this filing means.